Physical Comorbidities in Depression Co-Occurring with Anxiety: A Cross Sectional Study in the Czech Primary Care System
Abstract
:1. Introduction
2. Experimental Section
3. Results and Discussion
3.1. Participants
Type of the Depressive Episode | Mild | Moderate | Severe | Severe with Psychotic Symptoms | Total |
---|---|---|---|---|---|
Gender | |||||
Men | 824 | 808 | 151 | 19 | 1802 |
Women | 1105 | 1132 | 203 | 22 | 2462 |
Age | |||||
18–34 years | 644 | 469 | 61 | 7 | 1181 |
35–49 years | 824 | 665 | 113 | 13 | 1615 |
50–65 years | 304 | 513 | 95 | 9 | 921 |
>65 years | 157 | 293 | 85 | 12 | 547 |
Lifetime number of depressive episodes | |||||
1 | 1589 | 869 | 78 | 7 | 2543 |
2 | 278 | 832 | 134 | 11 | 1255 |
3 | 33 | 149 | 90 | 13 | 285 |
>4 | 29 | 90 | 52 | 10 | 181 |
Length of the current depressive episode | |||||
<1 month | 550 | 168 | 35 | 4 | 757 |
1–3 months | 918 | 972 | 116 | 15 | 2021 |
3–6 months | 325 | 615 | 139 | 8 | 1087 |
6–12 months | 90 | 132 | 50 | 10 | 282 |
>12 months | 46 | 53 | 14 | 4 | 117 |
Number of People with Depression | Neurologists | Psychiatrists | GPs | Total |
---|---|---|---|---|
<30 | 12 | 29 | 30 | 71 |
30–74 | 11 | 5 | 16 | 32 |
75–149 | 9 | 17 | 10 | 36 |
150–299 | 3 | 20 | 5 | 28 |
>300 | 5 | 28 | 1 | 34 |
Total | 40 | 99 | 62 | 201 |
3.2. Outcomes
Prevalence of Comorbidity | GAD | Panic Dis. | PTSD | SAD | Agora Phob. | Other Phob. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | |
Pain | 315 (40%) | 474 (60%) | 182 (33%) | 373 (67%) | 108 (37%) | 185 (63%) | 86 (21%) | 320 (79%) | 25 (18%) | 112 (82%) | 14 (16%) | 76 (84%) |
Hypertension | 207 (26%) | 582 (74%) | 110 (20%) | 445 (80%) | 81 (28%) | 212 (72%) | 93 (23%) | 313 (77%) | 36 (26%) | 101 (74%) | 26 (29%) | 64 (71%) |
Diabetes Mellitus | 77 (10%) | 712 (90%) | 49 (9%) | 506 (91%) | 39 (13%) | 254 (87%) | 62 (15%) | 344 (85%) | 24 (18%) | 113 (82%) | 13 (14%) | 77 (86%) |
Cardiovascular | 66 (8%) | 723 (92%) | 42 (8%) | 513 (92%) | 27 (9%) | 266 (91%) | 48 (12%) | 358 (88%) | 14 (10%) | 123 (90%) | 7 (8%) | 83 (92%) |
Neoplasms | 39 (5%) | 750 (95%) | 32 (6%) | 523 (94%) | 18 (6%) | 275 (94%) | 17 (4%) | 389 (96%) | 5 (4%) | 132 (96%) | 3 (3%) | 87 (97%) |
Organic Diseases of Nervous System | 44 (6%) | 745 (94%) | 18 (3%) | 537 (97%) | 12 (4%) | 281 (96%) | 26 (6%) | 380 (94%) | 6 (4%) | 131 (96%) | 3 (3%) | 87 (97%) |
Endocrine Diseases | 35 (4%) | 754 (96%) | 19 (3%) | 536 (97%) | 11 (4%) | 282 (96%) | 25 (6%) | 381 (94%) | 10 (7%) | 127 (93%) | 3 (3%) | 87 (97%) |
Gastrointestinal Diseases | 70 (9%) | 719 (91%) | 43 (8%) | 512 (92%) | 25 (9%) | 268 (91%) | 41 (10%) | 365 (90%) | 8 (6%) | 129 (94%) | 6 (7%) | 84 (93%) |
Total n=4.264 (100%) | 789 (18.5%) | 555 (13.0%) | 293 (6.9%) | 406 (9.5%) | 137 (3.2%) | 90 (2.1%) |
Comorbidity | Pain | Hypertension | Diabetes Mellitus | Cardiovascular | ||||||||
OR | p | 95% CI | OR | p | 95% CI | OR | p | 95% CI | OR | p | 95% CI | |
GAD | 2.78 | <0.001 | 2.35–3.29 | 1.42 | <0.001 | 1.18–1.70 | 1.16 | 0.265 | 0.89–1.51 | 1.31 | 0.066 | 0.98–1.74 |
Panic Disorder | 1.77 | <0.001 | 1.45–2.14 | 0.91 | 0.394 | 0.73–1.13 | 1.01 | 0.942 | 0.74–1.39 | 1.13 | 0.487 | 0.80–1.58 |
PTSD | 2.06 | <0.001 | 1.60–2.64 | 1.46 | 0.005 | 1.12–1.91 | 1.67 | 0.004 | 1.17–2.39 | 1.41 | 0.100 | 0.93–2.14 |
SAD | 0.88 | 0.335 | 0.69–1.14 | 1.12 | 0.377 | 0.87–1.43 | 2.06 | <0.001 | 1.53–2.76 | 1.98 | <0.001 | 1.42–2.75 |
Agora Phobia | 0.74 | 0.171 | 0.47–1.14 | 1.34 | 0.140 | 0.91–1.97 | 2.30 | <0.001 | 1.46–3.62 | 1.57 | 0.115 | 0.89–2.77 |
Other Phobia | 0.61 | 0.086 | 0.34–1.08 | 1.53 | 0.071 | 0.96–2.42 | 1.79 | 0.053 | 0.98–3.25 | 1.15 | 0.731 | 0.53–2.50 |
Comorbidity | Neoplasms | Organic Diseases of Nervous System | Endocrine Diseases | Gastrointestinal Diseases | ||||||||
OR | p | 95% CI | OR | p | 95% CI | OR | p | 95% CI | OR | p | 95% CI | |
GAD | 1.62 | 0.011 | 1.11–2.36 | 1.41 | 0.053 | 0.99–1.99 | 1.34 | 0.132 | 0.91–1.98 | 1.74 | <0.001 | 1.31–2.32 |
Panic Disorder | 1.91 | 0.001 | 1.28–2.86 | 0.72 | 0.183 | 0.44–1.17 | 0.96 | 0.872 | 0.59–1.57 | 1.39 | 0.056 | 0.99–1.96 |
PTSD | 1.95 | 0.009 | 1.17–3.24 | 0.94 | 0.848 | 0.52–1.71 | 1.07 | 0.838 | 0.57–2.00 | 1.52 | 0.054 | 0.99–2.35 |
SAD | 1.25 | 0.391 | 0.75–2.10 | 1.60 | 0.030 | 1.04–2.46 | 1.94 | 0.003 | 1.25–3.02 | 1.92 | <0.001 | 1.35–2.73 |
Agora Phobia | 1.06 | 0.895 | 0.43–2.64 | 1.02 | 0.970 | 0.44–2.34 | 2.23 | 0.016 | 1.14–4.33 | 0.98 | 0.953 | 0.47–2.02 |
Other Phobia | 0.97 | 0.952 | 0.30–3.09 | 0.76 | 0.643 | 0.24–2.43 | 0.94 | 0.914 | 0.29–3.00 | 1.13 | 0.774 | 0.49–2.61 |
Comorbidity | Pain | Hypertension | Diabetes Mellitus | Cardiovascular | ||||||||
OR | p | 95% CI | OR | p | 95% CI | OR | p | 95% CI | OR | p | 95% CI | |
GAD | 2.49 | <0.001 | 2.10-2.96 | 1.19 | 0.095 | 0.97–1.45 | 0.86 | 0.308 | 0.65–1.15 | 1.06 | 0.731 | 0.77–1.44 |
Panic Disorder | 1.75 | <0.001 | 1.43-2.15 | 0.94 | 0.662 | 0.73–1.22 | 0.9 | 0.561 | 0.63–1.28 | 1.15 | 0.468 | 0.78–1.68 |
PTSD | 1.87 | <0.001 | 1.45-2.43 | 1.55 | 0.004 | 1.15–2.10 | 1.63 | 0.013 | 1.11–2.39 | 1.49 | 0.081 | 0.95–2.34 |
SAD | 0.76 | 0.042 | 0.59-0.99 | 0.91 | 0.501 | 0.67–1.20 | 1.71 | 0.001 | 1.23–2.37 | 1.64 | 0.008 | 1.14–2.36 |
Agora Phobia | 0.71 | 0.136 | 0.45-1.11 | 1.61 | 0.034 | 1.04–2.50 | 2.51 | <0.001 | 1.51–4.18 | 1.75 | 0.079 | 0.94–3.27 |
Other Phobia | 0.6 | 0.086 | 0.33-1.07 | 1.75 | 0.034 | 1.04–2.92 | 2.22 | 0.013 | 1.18–4.20 | 1.35 | 0.469 | 0.60–3.05 |
Comorbidity | Neoplasms | Organic Diseases of Nervous System | Endocrine Diseases | Gastrointestinal Diseases | ||||||||
OR | p | 95% CI | OR | p | 95% CI | OR | p | 95% CI | OR | p | 95% CI | |
GAD | 1.25 | 0.263 | 0.85–1.84 | 1.11 | 0.572 | 0.77–1.60 | 1.05 | 0.794 | 0.71–1.57 | 1.5 | 0.006 | 1.12–2.02 |
Panic Disorder | 1.63 | 0.025 | 1.06–2.50 | 0.64 | 0.102 | 0.38–1.09 | 0.78 | 0.337 | 0.48–1.29 | 1.26 | 0.198 | 0.89–1.78 |
PTSD | 1.66 | 0.058 | 0.98–2.82 | 0.89 | 0.725 | 0.48–1.67 | 0.87 | 0.675 | 0.46–1.65 | 1.39 | 0.146 | 0.89–2.15 |
SAD | 0.98 | 0.941 | 0.57–1.68 | 1.31 | 0.247 | 0.83–2.06 | 1.55 | 0.059 | 0.98–2.44 | 1.59 | 0.012 | 1.11–2.28 |
Agora Phobia | 0.93 | 0.886 | 0.37–2.38 | 1.2 | 0.799 | 0.47–2.67 | 1.7 | 0.134 | 0.85–3.39 | 0.76 | 0.46 | 0.36–1.59 |
Other Phobia | 1.14 | 0.823 | 0.35–3.71 | 0.82 | 0.739 | 0.25–2.67 | 0.98 | 0.975 | 0.30–3.17 | 1.21 | 0.664 | 0.52–2.81 |
3.3. Discussion
4. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Nutt, D.; Argyropoulos, S.; Hood, S.; Potokar, J. Generalized anxiety disorder: A comorbid disease. Eur. Neuropsychopharmacol. 2006. [Google Scholar] [CrossRef] [PubMed]
- Braam, A.W.; Copeland, J.R.; Delespaul, P.A.; Beekman, A.T.; Como, A.; Dewey, M.; Fichter, M.; Holwerda, T.J.; Lawlor, B.A.; Lobo, A.; et al. Depression, subthreshold depression and comorbid anxiety symptoms in older Europeans: Results from the EURODEP concerted action. J. Affect Disord. 2014, 155, 266–272. [Google Scholar] [CrossRef] [PubMed]
- Fava, M.; Rankin, M.A.; Wright, E.C.; Alpert, J.E.; Nierenberg, A.A.; Pava, J.; Rosenbaum, J.F. Anxiety disorders in major depression. Compr. Psychiatry 2000. [Google Scholar] [CrossRef]
- King-Kallimanis, B.; Gum, A.M.; Kohn, R. Comorbidity of depressive and anxiety disorders for older Americans in the national comorbidity survey-replication. Am. J. Geriatr. Psychiatry 2009, 17, 782–792. [Google Scholar] [CrossRef] [PubMed]
- Zimmerman, M.; McDermut, W.; Mattia, J.I. Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am. J. Psychiatry 2000, 157, 1337–1340. [Google Scholar] [CrossRef] [PubMed]
- Gorman, J.M. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996, 4, 160–168. [Google Scholar] [CrossRef]
- Merikangas, K.R.; Zhang, H.; Avenevoli, S.; Acharyya, S.; Neuenschwander, M.; Angst, J. Longitudinal trajectories of depression and anxiety in a prospective community study. Arch. Gen. Psychiatry 2003, 60, 993–1000. [Google Scholar] [PubMed]
- Sherbourne, C.D.; Wells, K.B. Course of depression in patients with comorbid anxiety disorders. J. Affect. Disord. 1997, 43, 245–250. [Google Scholar] [CrossRef]
- Vogelzangs, N.; Seldenrijk, A.; Beekman, A.T.; van Hout, H.P.; de Jonge, P.; Penninx, B.W. Cardiovascular disease in persons with depressive and anxiety disorders. J. Affect. Disord. 2010, 125, 241–248. [Google Scholar] [CrossRef] [PubMed]
- Scott, K.; Bruffaerts, R.; Tsang, A.; Ormel, J.; Alonso, J.; Angermeyer, M.; Benjet, C.; Bromet, E.; de Girolamo, G.; de Graaf, R.; et al. Depression–anxiety relationships with chronic physical conditions: Results from the World Mental Health Surveys. J. Affect. Disord. 2007, 103, 113–120. [Google Scholar] [CrossRef] [PubMed]
- Stein, D.J.; Aguilar-Gaxiola, S.; Alonso, J.; Bruffaerts, R.; de Jonge, P.; Liu, Z.; Miguel Caldas-de-Almeida, J.; O’Neill, S.; Viana, M.C.; Al-Hamzawi, A.O.; et al. Associations between mental disorders and subsequent onset of hypertension. Gen. Hosp. Psychiatry 2014, 36, 142–149. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bhattacharya, R.; Shen, C.; Sambamoorthi, U. Excess risk of chronic physical conditions associated with depression and anxiety. BMC Psychiatry 2014. [Google Scholar] [CrossRef] [PubMed]
- Roy, T.; Lloyd, C.E. Epidemiology of depression and diabetes: A systematic review. J. Affect. Disord. 2012. [Google Scholar] [CrossRef]
- Romera, I.; Fernandez-Perez, S.; Montejo, A.L.; Caballero, F.; Caballero, L.; Arbesu, J.A.; Gilaberte, I. Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: Prevalence of painful somatic symptoms, functioning and health status. J. Affect. Disord. 2010, 127, 160–168. [Google Scholar] [CrossRef] [PubMed]
- Petersen, T.; Andreotti, C.F.; Chelminski, I.; Young, D.; Zimmerman, M. Do comorbid anxiety disorders impact treatment planning for outpatients with major depressive disorder? Psychiatry Res. 2009. [Google Scholar] [CrossRef] [PubMed]
- Forsman, A.K.; Ventus, D.B.; van der Feltz-Cornelis, C.M.; Wahlbeck, K. Public mental health research in Europe: A systematic mapping for the ROAMER project. Eur. J. Public Health 2014, 24, 955–960. [Google Scholar] [CrossRef] [PubMed]
- Patten, S.B.; Williams, J.V.; Lavorato, D.H.; Modgill, G.; Jette, N.; Eliasziw, M. Major depression as a risk factor for chronic disease incidence: Longitudinal analyses in a general population cohort. Gen. Hosp. Psychiatry 2008, 30, 407–413. [Google Scholar] [CrossRef] [PubMed]
- Beaudet, M.P. Depression. Health Rep. 1996, 7, 11–25. [Google Scholar] [PubMed]
- Patten, S.B. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J. Affect. Disord. 2001. [Google Scholar] [CrossRef]
- Kessler, R.C.; Crum, R.M.; Warner, L.A.; Nelson, C.B.; Schulenberg, J.; Anthony, J.C. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch. Gen. Psychiatry 1997, 54, 313–321. [Google Scholar] [CrossRef] [PubMed]
- Katon, W.; Von, K.M.; Lin, E.; Lipscomb, P.; Russo, J.; Wagner, E.; Polk, E. Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs. Gen. Hosp. Psychiatry 1990, 12, 355–362. [Google Scholar] [CrossRef]
- Hirschfeld, R.M. The comorbidity of major depression and anxiety disorders: Recognition and management in primary care. Prim. Care Companion J. Clin. Psychiatry 2001, 3, 244–254. [Google Scholar] [CrossRef] [PubMed]
- Kessler, R.C.; Nelson, C.B.; McGonagle, K.A.; Liu, J.; Swartz, M.; Blazer, D.G. Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US National Comorbidity Survey. Br. J. Psychiatry Suppl. 1996, 30, 17–30. [Google Scholar]
- Olfson, M.; Fireman, B.; Weissman, M.M.; Leon, A.C.; Sheehan, D.V.; Kathol, R.G.; Hoven, C.; Farber, L. Mental disorders and disability among patients in a primary care group practice. Am. J. Psychiatry 1997, 154, 1734–1740. [Google Scholar] [CrossRef] [PubMed]
- Brown, L.C.; Majumdar, S.R.; Newman, S.C.; Johnson, J.A. History of depression increases risk of type 2 diabetes in younger adults. Diabet. Care 2005, 28, 1063–1067. [Google Scholar] [CrossRef]
- Eaton, W.W.; Armenian, H.; Gallo, J.; Pratt, L.; Ford, D.E. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabet. Care 1996, 19, 1097–1102. [Google Scholar] [CrossRef]
- DeJean, D.; Giacomini, M.; Vanstone, M.; Brundisini, F. Patient experiences of depression and anxiety with chronic disease: A systematic review and qualitative meta-synthesis. Ont. Health Technol. Assess Ser. 2013, 13, 1–33. [Google Scholar] [PubMed]
- Henningsen, P.; Zimmermann, T.; Sattel, H. Medically unexplained physical symptoms, anxiety, and depression: A meta-analytic review. Psychosom. Med. 2003, 65, 528–533. [Google Scholar] [CrossRef] [PubMed]
- Gureje, O. Comorbidity of pain and anxiety disorders. Curr. Psychiatry Rep. 2008, 10, 318–322. [Google Scholar] [CrossRef] [PubMed]
- Gureje, O.; von Korff, M.; Kola, L.; Demyttenaere, K.; He, Y.; Posada-Villa, J.; Angermeyer, M.C.; Levinson, D.; de Girolamo, G.; Uda, H.; et al. The relation between multiple pains and mental disorders: Results from the World Mental Health Surveys. Pain 2008, 135, 82–91. [Google Scholar] [Green Version]
- Van Dijk, G.; van Heijningen, S.; Reijne, A.C.; Nyakas, C.; van der Zee, E.A.; Eisel, U.L. Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. Front. Neurosci. 2015. [Google Scholar] [CrossRef] [PubMed]
- Prince, M.J.; Harwood, R.H.; Thomas, A.; Mann, A.H. A prospective population-based cohort study of the effects of disablement and social milieu on the onset and maintenance of late-life depression. The Gospel Oak Project VII. Psychol. Med. 1998, 28, 337–350. [Google Scholar] [CrossRef] [PubMed]
- Cohen, S.; Rodriquez, M.S. Pathways linking affective disturbances and physical disorders. Health Psychol. 1995, 14, 374–380. [Google Scholar] [CrossRef] [PubMed]
- Pickering, T.G. Mental stress as a causal factor in the development of hypertension and cardiovascular disease. Curr. Hypertens. Rep. 2001, 3, 249–254. [Google Scholar] [CrossRef] [PubMed]
- Horacek, J.; Kuzmiakova, M.; Hoschl, C.; Andel, M.; Bahbonh, R. The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 1999, 24, 785–797. [Google Scholar] [CrossRef]
- Brunerova, L.; Potockova, J.; Horacek, J.; Suchy, J.; Andel, M. Central dopaminergic activity influences metabolic parameters in healthy men. Neuroendocrinology 2013, 97, 132–138. [Google Scholar] [CrossRef] [PubMed]
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Winkler, P.; Horáček, J.; Weissová, A.; Šustr, M.; Brunovský, M. Physical Comorbidities in Depression Co-Occurring with Anxiety: A Cross Sectional Study in the Czech Primary Care System. Int. J. Environ. Res. Public Health 2015, 12, 15728-15738. https://doi.org/10.3390/ijerph121215015
Winkler P, Horáček J, Weissová A, Šustr M, Brunovský M. Physical Comorbidities in Depression Co-Occurring with Anxiety: A Cross Sectional Study in the Czech Primary Care System. International Journal of Environmental Research and Public Health. 2015; 12(12):15728-15738. https://doi.org/10.3390/ijerph121215015
Chicago/Turabian StyleWinkler, Petr, Jiří Horáček, Aneta Weissová, Martin Šustr, and Martin Brunovský. 2015. "Physical Comorbidities in Depression Co-Occurring with Anxiety: A Cross Sectional Study in the Czech Primary Care System" International Journal of Environmental Research and Public Health 12, no. 12: 15728-15738. https://doi.org/10.3390/ijerph121215015
APA StyleWinkler, P., Horáček, J., Weissová, A., Šustr, M., & Brunovský, M. (2015). Physical Comorbidities in Depression Co-Occurring with Anxiety: A Cross Sectional Study in the Czech Primary Care System. International Journal of Environmental Research and Public Health, 12(12), 15728-15738. https://doi.org/10.3390/ijerph121215015